Drug Profile
Delgocitinib - Japan Tobacco/LEO Pharma
Alternative Names: CORECTIM; JTE-052; JTE-052A; LEO 124249; LEO 124249 cream; LP-0133Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Japan Tobacco
- Developer Japan Tobacco; LEO Pharma
- Class Anti-inflammatories; Antiallergics; Antipsoriatics; Azetidines; Nitriles; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules; Spiro compounds
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
- Preregistration Eczema
- Phase II Alopecia areata; Autoimmune disorders; Discoid lupus erythematosus; Hypersensitivity; Inverse psoriasis
Most Recent Events
- 09 Mar 2024 Efficacy and adverse events data from a phase III OLE DELTA-3 trial in Eczema released by LEO Pharma
- 24 Jan 2024 Efficacy and adverse events data from phase III DELTA FORCE trial for Eczema released by LEO Pharma
- 05 Dec 2023 LEO Pharma completes a phase III trial for Eczema (Treatment-experienced) in Austria, Canada, France, Germany, Italy, Norway, Poland, Slovakia, Spain, and the UK (topical, Cream) (NCT05259722) (EudraCT2021-003543-16)